20+
Years In Biotech
1
Startups Initiated
1,176
LinkedIn Followers
Shannon’s Journey
Appointed as a tenure-track Assistant Professor in the Department of Ophthalmology at the University of Florida.
2012
Co-founded Atsena Therapeutics as Founder and Director to advance clinical gene therapy programs for inherited retinal diseases including LCA1 and XLRS.
2020
Appointed Chief of the Division of Cellular and Molecular Therapy at the University of Florida’s Department of Pediatrics.
2024
2017
Promoted to Associate Professor of Ophthalmology at the University of Florida following receipt of tenure.
2021
Became Professor of Pediatrics at the University of Florida, leading the Division of Cellular and Molecular Therapy.
2025
Assumed the role of Chief Scientific Officer at Atsena Therapeutics.
About Atsena Therapeutics
Founded - 2020 | Durham, NC | Stage -Private biotech, clinical-stage / venture-backed
Highlight
Shannon Boye builds gene therapy and gene-regulation companies focused on inherited retinal disease and advanced genetic medicine.
Problem
Patients with inherited retinal diseases have historically had limited treatment options, even when the underlying genetic drivers are known. Translating gene therapy research into clinical programs requires deep scientific specialization, capital, and regulatory execution.
USP
Dr. Boye’s work connects academic gene therapy research with venture-backed biotechnology platforms. She serves as Co-Founder, Director, and Chief Scientific Officer of Atsena Therapeutics, a clinical-stage company based in Durham, NC.
Key Milestones
2020
Atsena Therapeutics launched to develop gene therapies for inherited retinal diseases.
2023
Shannon Boye named University of Florida Innovator of the Year.
2024
Atsena licensed its LCA1 gene therapy program to Nippon Shinyaku.
In Their Own Words:
"I've focused the last 20 years of my career on developing gene therapies."
Connect: